Key points from article :
TRAILBLAZER-ALZ Phase 2 study assessed the safety, tolerability and efficacy of donanemab in patients with Alzheimer's disease.
Donanemab, an investigational antibody showed significant slowing of decline in a composite measure of cognition and daily function.
Showed consistent improvements in primary and all prespecified secondary endpoints measuring cognition and function.
"Donanemab is a potential therapy for people living with Alzheimer's disease, the only leading cause of death without a treatment," - Mark Mintun, vice president, Eli Lilly and Company.
Treatment has been shown to rapidly result in high levels of amyloid plaque clearance.
"The positive results of donanemab support its rapid and deep plaque clearance for the potential treatment of Alzheimer's disease," - Daniel Skovronsky, Lilly's chief scientific officer.
Full results of the TRAILBLAZER-ALZ study will be submitted for publication in a peer-reviewed clinical journal.
